Sagar DusaneMMS- B-11-(2015-17)AIAIMS- Mumbai 01

Perspective Management

History

•  Sushruta Samhita, an Indian Ayurvedic treatise 6th century BC

• Ancient Egyptian papyri such as the Ebers Papyrus of 1550 BC.

• Ancient Greece, Diocles of Carystus (4th century BC) medicinal properties of plants

• Galen is the father of pharmacy• Prof. William Procter, father of American

pharmacy

GlaxoSmithKline plc (GSK)

• Founded 2000; 15 years ago

• Headquarters- Brentford, London, United Kingdom

• Products- Pharmaceuticals, vaccines, oral healthcare

products, nutritional products, 

over-the-counter medicines.

• Number of employees - 96,575 (2015)

• Slogan- "Do more, feel better, live longer"

Pfizer, Inc.

• Founded 1849; 166 years ago• Headquarters New York City, New York, United

States• Number of employees- 78,000 (2014)• Slogan- Doing things differently

Products of GSK

The GSK India product portfolio includes prescription medicines and vaccines. GSK prescription medicines range across therapeutic areas and GSK also offer a range of vaccines.

Category of Drugs

• Antibiotic drugs • Analgesic drugs• Anticancer drugs• Vaccines• Derma products

Antibiotics

• Augmentin DDS• Augmentin (I.V.)• Augmentin tabs• Cetzin A

ANALGESICS

• Calpol• Calpol T

VACCINES

•Engerix-B : Hepatitis B Vaccine•Havrix : Inactivated Hepatitis A virus Vaccine

Products of Pfizer

Pfizer products reflect their focus on innovation. A great insight leads to strenuous research, which in turn forms the basis of a great product. There can be no compromise when it comes to patient health. At Pfizer, every product is designed to be the best in the market

Anti-Allergic

• LC-OD M (Levocetrizine + Montelukast)• Levocetrizine Group (Levocetrizine)• LC-OD Plus (Levocetrizine + Montelukast

+Dihydrochloride)

Anti-Diabetic

• Amlogard-Met (Amlodipine + Metoprolol)• Bidiab (Metformin)• Immediab (Glimepiride)• Immediab-M (Metformin Glimepiride)

Multivitamins

Becosule Capsules (Vit.B- Complex+ Vit.C)

Comparison

v/s

Market segmentation

Market segmentation

9147.74; 28%

5826.39; 17%

4702.38; 14%

2749.39; 8%

2705.95; 8%

2514.09; 7%

1838.96; 5%

2409.11; 7%

1882.4; 6%

Respiratory

Central nervous system

Anti-Virals

Anti-Bacterials

Metabolic

Vaccines

Oncology and emesis

Cardiovascular

Other

3538; 10%

5763; 15%

2633; 7%

1372; 4%

0; 0%

1669; 5%

2434; 7%

17958; 48%

1368; 4%

Respiratory

Central nervous system

Urology

Ophthalmology

Vaccines

Artrithis

Oncology and emesis

Cardiovascular

Other

Corporate views and values

Mission - to improve the quality of human

life

Purpose - dedicated to better health and

greater access to healthcare.

Research based pharmaceutical company

Shape a flexible R&D organisation that can respond to the challenges and the opportunities

- become the world's most valued company to patients, customers, colleagues, investors, business partners.

- dedicated to better health and greater access to healthcare.

Growth through innovation

Research based pharmaceutical company

Customer - understanding and responding to their

often changing needs.

Personnel policy -GSK business employs over 100,000

people in 116 countries Over 15,000 people work in research

teams to discover new medicines For employees, we create an environment

that allows them to do their best work by being themselves

Stakeholders - we must provide the right

information in a timely and effective way.

- deeply committed to meeting the needs of our customers, and we constantly focus on customer satisfaction

- Pfizer employs 122,000 people in 60 countries and has sales in more than 150 countries.

People are the cornerstone of Pfizer's success, we value our diversity as a source of strength, and we are proud of Pfizer's history of treating people with respect and dignity

- We work with stakeholders to share knowledge, skills and goals on how to prevent or manage diseases, how to get medicine to the people who need it, and how to promote good health.

Corporate views and values

Events (risks)

• Product Recall & Litigations • Patent Expiration • BRIC Competition & Generics• Free Access & Price Dumping • Public opinion pressure

Markets (opportunities)

• Cancer Treatment• Pandemic & Bioterrorism• Healthcare & Animal• Online Pharmacy • Developing World

Market Area

Market Area GlaxoSmithKline Pharmaceuticals Ltd.

Parent Company GlaxoSmithKline Plc

Category Pharmaceutical and Healthcare companies

Sector Health Care

Tagline/ Slogan Do more, feel better, live longer

USPGlaxoSmithKline is the UK’s largest and world’s second  largest pharmaceutical company

Overview (Glaxosmithkline)

GSK Worldwide-• Focus• Strength• Trade• Rnd• Social responsibility programmes

SWOT Analysis for GSKStrength

• Top 5 largest pharmaceutical companies• Innovation• Previous achievements• Strong R&d focus• Global presence • Employees strength

Weakness• Safety of drugs affects• Patent expiry for a number of bulk-buster products

Opportunity• Good network with competitor• Increasing awareness about healthcare needs• Global penetration • Increasing demand for quality healthcare solutions

Threats• Risk of unsuccessful new Products• Regulatory environment• Economic meltdown

Patient safety

Intellectual property

Supply chain and quality

Legal, regulatory, and

compliance

Economic and financial risks

RISK OF GSK

Pfizer

Pfizer

Parent Company Pfizer Ltd

Category Pharmaceutical

Sector Health care

Tagline/ Slogan Doing things differently

USPPfizer Inc discovers, develops, manufactures, and markets leading prescription drugs

SWOT Analysis for Pfizer Strength

• Largest pharmaceutical company spread over 50 countries• Excellent research and development (R&D) • 100,000 employees • Strong brand name and recall globally

Weakness

• Tough competition from other major pharmacy brands • Negative brand image due to involvement in largest healthcare fraud of marketing its drug illegally

Opportunity

• Strategic agreements with other pharmaceutical companies • Increasing awareness about healthcare needs• Global penetration through mergers and acquisitions• Increasing demand for quality healthcare solutions

Threats

• Risk of unsuccessful new Products• Regulatory environment is becoming more & more stringent• Economic slowdown in European markets

Geographic

Foreign exchange

Legal

Integrated risk

RISK FOR PFIZER

PORTER`S FIVE FORCES ANALYSIS

External analysis by Porter’s five forces model

Organization Threat of New entrants

Suppliers bargaining

power

Buyers Bargaining

power

Rivalry from competitors

Threat of product

substitute

GlaxoSmithKline

Low Low Low High High

Pfizer Low Low Low High High

Top 10 Exporting countries1. Germany: (15.2%)

2. Switzerland: (10.5%)

3. Belgium: (9%)

4. France: (7.6%)

5. United States: (7.2%)

6. United Kingdom: (6.9%)

7. Italy: (6.5%)

8. Ireland: (5.8%)

9. Netherlands: (4.7%)

10. India: (3.1%)

ISSUES AND SOLUTIONS

Company Overview

• Research based, global pharmaceutical company• Discovers, develops, manufactures and markets prescription drugs

The Problem With Pfizer's $17 Billion Buy

Buying hospira hsp +%, the Lake Forest, Illinois-based hospital-focused drug maker, for $17 billion in cash and assumed debt to beef up its generic business

Pfizer accused of testing new drug without ethical approval

• Pfizer did not obtain official approval before testing a new drug on children during a meningitis epidemic in Nigeria five years

• Pfizer said that 15000 people died during the epidemic

Most ethical challenges in history

• 1996: Eleven children died and many were disabled • 1998: The FDA approved Trovan for use in adults only•1999: The European Union banned Trovan.

• 2006: A Nigerian panel concluded that the Pfizer trial was an “illegal

• 2010: Pfizer finally settled the suits for about $75 million

Pfizer’s Latest Twist on ‘Pay for Delay’

• The controversial practice, known as "pay for delay"

•  In 2008, the company settled patents litigations with

Ranbaxy

•  Agreed to pay the $2.3 billion in fines

•  Glaxosmithkline drug issue• Risked damaging the health of people around the world

GlaxoSmithKline's bribes are evidence that Big

Pharma isn't working

• Animal studies for an experimental therapy

• Bribery of doctors in a position to prescribe its drugs.

GlaxoSmithKline's China R&D audit found ethical

No doctors to promote its drugsStop tying compensation for sales representatives

GlaxoSmithKline to Quit Paying Doctors for Promotional Talks